Ipsen To File Cabozantinib For Liver Cancer In 1H 2018
Exelixis and Ipsen's Phase III CELESTIAL trial succeeds: cabozantinib meets primary overall survival endpoint in patients with advanced liver cancer.
You may also be interested in...
CHMP Nod For Ipsen's Mainstay Cancer Drug Cabometyx In First-Line RCC
The EMA's drug assessment committee, the CHMP, has given Ipsen's Cabometyx a positive recommendation for use in first-line kidney cancer, a label extension that will add more weight to the company's standing as a cancer specialist.
Exelixis CEO Eyes Expanded Indications For Cabozantinib
In a video interview at the Biotech Showcase, Exelixis CEO Michael Morrissey discusses the recent launch of cabozantinib in first-line renal cell carcinoma and looks ahead to filing soon in liver cancer.
Europe's Biopharma Sector Could Be In For Bumper Year
The Belgian biotechs Ablynx and Galapagos are among the companies that are likely to have a very interesting 2018, according to analysts, and the sector in Europe as a whole is set for consolidation and more drugs getting to market, helped by a supportive regulatory landscape.